ATOSSA THERAPEUTICS I

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

28 يونيو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

17 يونيو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa to Present at the Sidoti Small-Cap Investor Conference

05 يونيو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

28 مايو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

15 مايو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

13 مايو 2024 08:50:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

07 مايو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

29 أبريل 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

15 أبريل 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

11 أبريل 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

09 أبريل 2024 11:59:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

01 أبريل 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

19 مارس 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

18 مارس 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

12 مارس 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

06 مارس 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

22 فبراير 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

07 فبراير 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Issues Letter to Shareholders

09 يناير 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

04 ديسمبر 2023 08:30:00 بحسب Nasdaq GlobeNewswire